Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers
NCT ID: NCT00446472
Last Updated: 2010-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2007-04-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
NCT00034788
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
NCT00389636
Effect of rhGM-CSF on the Healing of Venous Leg Ulcers
NCT04823962
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
NCT00069446
Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer
NCT04689425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Application of casts or cast braces \[below knee, removable boots with protective padding\] to protect and immobilize the ankle and foot have been demonstrated to provide superior wound healing than less cumbersome types of shoe gear (1-3). The benefit of casting may be the result of more effective off-loading of pressure than can be achieved with other devices, but the inability of patients to remove their casts also appears to an important factor, as non-compliance with removable cast-braces has been shown to be a pervasive and significant issue (4,5). One critical concept in diabetic foot ulcer management is the relation between chronically and limb loss - for each year a wound persists, a patient has a 25% risk for major amputation due to complications from infection (6-8). Limb loss has a profound effect on Diabetics' quality of life and rate of lower limb loss among diabetics is four per 1,000 person years in comparison with three per 10,000 person years (9-10).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Randomized to Regranex gel
Regranex®
Regranex gel will be used for a total of 16 weeks
2
Placebo hydrogel will be used for a total of 16 weeks
Hydrogel
Placebo hydrogel will be applied for 16 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regranex®
Regranex gel will be used for a total of 16 weeks
Hydrogel
Placebo hydrogel will be applied for 16 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a history of compliance and reliability in following study required treatment regimen.
* Have diabetic mellitus Type I or Type II and have a glycohemoglobin Alc less than l0
* Presence of one or two ulcers in lower extremities
1. Wounds cannot be positioned more than 2.5cm proximal to the malleoli, but may involve any more distal position of the foot
2. Type 2 Diabetic Mellitus Neuropathic ulcers present at least for 3months with failure to heal
3. Post-operation wounds in DM patients with wound present for minimum 4 weeks after surgery and wound surface area has failed to decrease more than 20% in 4 weeks
4. Ulcer(s) must be stage II or III full-thickness (extending through the subcutaneous tissue or beyond - Wagner grade II or III)
5. No joint, tendon or bone exposure
6. Located on the lower extremity.
7. Ulcer size measures 1cm2 \< 16 cm2
8. No osteomyelitis affecting the area of the ulcer
9. If two wounds, both can be incorporated into one window when cast applied
* Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.
Exclusion Criteria
* Previous sensitivity to Regranex® Gel.
* Use of topical antibiotics, enzymatic debriders on the selected ulcer(s) within 30 days preceding randomization.
* Osteomyelitis affecting the area of the selected ulcer(s)
* Exposed bone, joint or tendon at ulcer site (Wagner III or higher)
* Presence of more than two full-thickness ulcers on targeted lower extremity
* Requirement for systemic antibiotics use within 7 days of study entry
* Inability to tolerate cast
* Presence of systemic or local cancer of any kind
* Life expectancy less than 1 year
* Subjects with end stage renal failure requiring chronic hemodialysis
* Concomitant use of Pletal or other vasodilators
* Ankle Brachial Index less or equal to 0.8 or toe pressure index less than 0.6
* ESR\>20
* Demonstration of poor compliance including a chronic alcohol, psychiatric condition or drug abuse problems
21 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heritage Medical Research Institute
OTHER
Southern California Institute for Research and Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
VA Long Beach Health Care System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aksone Nouvong, D.P.M.
Role: PRINCIPAL_INVESTIGATOR
VA Greater Los Angeles Healthcare System
Ian Gordon, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
VA Long Beach Healthcare System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Long Beach Healthcare System
Long Beach, California, United States
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001 Jun;24(6):1019-22. doi: 10.2337/diacare.24.6.1019.
Ha Van G, Siney H, Hartmann-Heurtier A, Jacqueminet S, Greau F, Grimaldi A. Nonremovable, windowed, fiberglass cast boot in the treatment of diabetic plantar ulcers: efficacy, safety, and compliance. Diabetes Care. 2003 Oct;26(10):2848-52. doi: 10.2337/diacare.26.10.2848.
Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, Gino M, Pritelli C, Morabito A. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diabetes Care. 2000 Dec;23(12):1746-51. doi: 10.2337/diacare.23.12.1746.
Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003 Sep;26(9):2595-7. doi: 10.2337/diacare.26.9.2595.
Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005 Mar;28(3):551-4. doi: 10.2337/diacare.28.3.551.
Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med. 1995 Sep;12(9):770-6. doi: 10.1111/j.1464-5491.1995.tb02078.x.
Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes. 1991 Oct;40(10):1305-13. doi: 10.2337/diab.40.10.1305.
Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5. doi: 10.1007/s004170050085.
U.S. Department of Health and Human Services. Healthy People 2010: Understanding and improving health, vol.2. Washington, DC: US Government Printing Office, 2000
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990 May;13(5):513-21. doi: 10.2337/diacare.13.5.513.
Related Links
Access external resources that provide additional context or updates about the study.
Southern California Institute for Research and Education (SCIRE) Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#778
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.